Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2024; 16(11): 1243-1254
Published online Nov 27, 2024. doi: 10.4254/wjh.v16.i11.1243
Current status of drug therapy for alveolar echinococcosis
Qin-Dong Jing, Ji-De A, Lin-Xun Liu, Hai-Ning Fan
Qin-Dong Jing, Lin-Xun Liu, Department of General Surgery, Qinghai Provincial People’s Hospital, Xining 810000, Qinghai Province, China
Qin-Dong Jing, School of Clinical Medicine, Qinghai University, Xining 810000, Qinghai Province, China
Ji-De A, Department of Hepatic Hydatidosis, Qinghai Provincial People’s Hospital, Xining 810007, Qinghai Province, China
Hai-Ning Fan, Department of Hepatobiliary and Pancreatic Surgery, Qinghai Province Research Key Laboratory for Echinococcosis, Affiliated Hospital of Qinghai University, Xining 810001, Qinghai Province, China
Co-first authors: Qin-Dong Jing and Ji-De A.
Co-corresponding authors: Lin-Xun Liu and Hai-Ning Fan.
Author contributions: Jing QD and A JD conceptualized and designed this research and obtained, analyzed, interpreted data, and prepared the initial draft of the manuscript, both authors have made crucial and indispensable contributions to the completion of the project, and therefore qualify as co first authors of the paper; Liu LX and Fan HN conducted a critical review of the important knowledge content in the manuscript, as co corresponding authors, they played an indispensable role in data interpretation and manuscript preparation; Fan HN conceptualized, designed, and supervised the entire process of the project; All the authors have read and approved the final manuscript.
Supported by the Guiding Program Project of Qinghai Provincial Health Commission, No. 2020-wjzdx-27.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Ning Fan, DPhil, Chief Physician, Professor, Department of Hepatobiliary and Pancreatic Surgery, Qinghai Province Research Key Laboratory for Echinococcosis, Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810001, Qinghai Province, China. fanhaining@medmail.com.cn
Received: July 18, 2024
Revised: September 13, 2024
Accepted: October 15, 2024
Published online: November 27, 2024
Processing time: 110 Days and 18.3 Hours
Core Tip

Core Tip: Our manuscript reviews the research on albendazole and other drugs in the treatment of alveolar echinococcosis (AE), with a particular focus on anti-angiogenic drugs, immunosuppressants, and the role of the immune microenvironment in AE. These areas represent significant parts of our manuscript and are currently in the exploratory phase, so extensive basic validation experiments are still needed.